Recent achievements in the management of Raynaud’s phenomenon

References

• RaynaudMLocal Asphyxia and Symmetrical Gangrene of the ExtremitiesLondonNew Sydenham Society1862
   Google Scholar
• LewisTExperiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud’s diseaseHeart1929157101
   Google Scholar
• LeRoyECMedsgerTAJrRaynaud’s phenomenon: a proposal for classificationClin Exp Rheumatol19921054854881458701
   PubMed Web of Science ®Google Scholar
• BakstRMerolaJFFranksAGJrSanchezMRaynaud’s phenomenon: pathogenesis and managementJ Am Acad Dermatol200859463365318656283
   PubMed Web of Science ®Google Scholar
• KahelehBMatucci-CerinicMRaynaud’s phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular toneArthritis Rheum199538147818557
   PubMedGoogle Scholar
• RajagopalanSPfenningerDKehrerCIncreased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud’s phenomenon: implications for vascular dysfunction and progression of diseaseArthritis Rheum20034871992200012847693
   PubMedGoogle Scholar
• KirchengastMMunterKEndothelin-1 and endothelin receptor antagonists in cardiovascular remodelingProc Soc Exp Biol Med1999221431232510460693
   PubMedGoogle Scholar
• BaumhakelMCustodisFSchlimmerNLaufsUBohmMImprovement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartanJ Pharmacol Exp Ther2008327369269818812494
   PubMedGoogle Scholar
• FriedrichEBTeoKKBohmMACE inhibition in secondary prevention: are the results controversial?Clin Res Cardiol2006952616716598512
   PubMedGoogle Scholar
• KawaguchiYTakagiKHaraMAngiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptorsArthritis Rheum200450121622614730619
   PubMedGoogle Scholar
• YardumianDAMackieIJBrennanECBullHMachinSJPlatelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteersHaemostasis198616120262422095
   PubMedGoogle Scholar
• BerteleVMussoniLdel RossoGDefective fibrinolytic response in atherosclerotic patients – effect of iloprost and its possible mechanism of actionThromb Haemost19886021411442464198
   PubMedGoogle Scholar
• FurspanPBChatterjeeSFreedmanRRIncreased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s diseaseArthritis Rheum20045051578158515146428
   PubMed Web of Science ®Google Scholar
• ChotaniMAFlavahanSMitraSDauntDFlavahanNASilent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteriesAm J Physiol20002784H1075H1083
   PubMed Web of Science ®Google Scholar
• BaileySREidAHMitraSFlavahanSFlavahanNARho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocationCirc Res200494101367137415087420
   PubMed Web of Science ®Google Scholar
• BaileySRMitraSFlavahanSFlavahanNAReactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteriesAm J Physiol20052891H243H250
   PubMed Web of Science ®Google Scholar
• BunkerCBTerenghiGSpringallDRPolakJMDowdPMDeficiency of calcitonin gene-related peptide in Raynaud’s phenomenonLancet19903368730153015331979366
   PubMedGoogle Scholar
• TehLSManningJMooreTTullyMPO’ReillyDJaysonMISustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenonBr J Rheumatol19953476366417670782
   PubMedGoogle Scholar
• FranksAGJrTopical glyceryl trinitrate as adjunctive treatment in Raynaud’s diseaseLancet19821826376776119495
   PubMed Web of Science ®Google Scholar
• KlecknerMJrAllenEVWakimKGThe effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud’s disease and Raynaud’s phenomenon; studies on blood flow and clinical manifestationsCirculation19513568168914831190
   PubMedGoogle Scholar
• Stosic-GrujicicSDMaksimovicDDStojkovicMBLukicMLPentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetesDev Immunol200183–421322111785671
   PubMedGoogle Scholar
• KinneyELNicholasGGGalloJPontorieroCZelisRThe treatment of severe Raynaud’s phenomenon with verapamilJ Clin Pharmacol198222174767037872
   PubMed Web of Science ®Google Scholar
• AbernethyDRSchwartzJBCalcium-antagonist drugsN Engl J Med1999341191447145710547409
   PubMed Web of Science ®Google Scholar
• OpieLHYusufSKublerWCurrent status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studiesProg Cardiovasc Dis200043217119611014332
   PubMedGoogle Scholar
• ThompsonAEPopeJECalcium channel blockers for primary Raynaud’s phenomenon: a meta-analysisRheumatology (Oxford)200544214515015546967
   PubMed Web of Science ®Google Scholar
• ThompsonAESheaBWelchVFenlonDPopeJECalcium-channel blockers for Raynaud’s phenomenon in systemic sclerosisArthritis Rheum20014481841184711508437
   PubMed Web of Science ®Google Scholar
• ScorzaRCaronniMMascagniBEffects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled studyClin Exp Rheumatol200119550350811579708
   PubMedGoogle Scholar
• Stosic-GrujicicSMaksimovicDBadovinacVAntidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide productionJ Autoimmun2001161475811221996
   PubMedGoogle Scholar
• WigleyFMWiseRASeiboldJRIntravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyAnn Intern Med199412031992067506013
   PubMed Web of Science ®Google Scholar
• KawaldABurmesterGRHuscherDSunderkotterCRiemekastenGLow versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center studyJ Rheumatol20083591830183718634152
   PubMed Web of Science ®Google Scholar
• WilkinsMRPaulGAStrangeJWSildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) studyAm J Resp Crit Care Med2005171111292129715750042
   PubMedGoogle Scholar
• FriesRShariatKvon WilmowskyHBohmMSildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapyCirculation2005112192980298516275885
   PubMed Web of Science ®Google Scholar
• LichtensteinJRUse of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et alArthritis Rheum2003481282283author reply 312528146
   PubMedGoogle Scholar
• KumanaCRCheungGTLauCSSevere digital ischaemia treated with phosphodiesterase inhibitorsAnn Rheum Dis200463111522152415479910
   PubMedGoogle Scholar
• BaumhaekelMSchefflerPBoehmMUse of tadalafil in a patient with a secondary Raynaud’s phenomenon not responding to sildenafilMicrovasc Res200569317817915896360
   PubMedGoogle Scholar
• RosatoELetiziaCProiettiMPlasma adrenomedullin and endothelin-1 levels are reduced and Raynaud’s phenomenon improved by daily tadalafil administration in male patients with systemic sclerosisJ Biol Regul Homeost Agents2009231232919321043
   PubMed Web of Science ®Google Scholar
• SchiopuEHsuVMImpensAJRandomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosisJ Rheumatol200936102264226819755613
   PubMed Web of Science ®Google Scholar
• MorelliSFerriCPolettiniEPlasma endothelin-1 levels, pulmonary hypertension and lung fibrosis in patients with systemic sclerosisAm J Med19959932552607653485
   PubMedGoogle Scholar
• KornJHMayesMMatucci CerinicMDigital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistArthritis Rheum200450123985399315593188
   PubMed Web of Science ®Google Scholar
• WernerCBaumhakelMTeoKKRAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selectionClin Res Cardiol200897741843118454336
   PubMed Web of Science ®Google Scholar
• Garcia-CarrascoMJimenez-HernandezMEscarcegaROTreatment of Raynaud’s phenomenonAutoimmunity reviews200881626818692160
   PubMedGoogle Scholar
• WoodHMErnstMERenin-angiotensin system mediators and Raynaud’s phenomenonAnn Pharmacother200640111998200217003081
   PubMedGoogle Scholar
• DziadzioMDentonCPSmithRLosartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis Rheum199942122646265510616013
   PubMed Web of Science ®Google Scholar
• PopeJFenlonDThompsonAPrazosin for Raynaud’s phenomenon in progressive systemic sclerosisCochrane Database Syst Rev20002CD00095610796398
   PubMedGoogle Scholar
• WiseRAWigleyFMWhiteBEfficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover studyArthritis Rheum200450123994400115593189
   PubMed Web of Science ®Google Scholar
• LaufsULa FataVPlutzkyJLiaoJKUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorsCirculation19989712112911359537338
   PubMed Web of Science ®Google Scholar
• RikitakeYLiaoJKROCKs as therapeutic targets in cardiovascular diseasesExp Rev Cardiovasc Ther200533441451
   PubMedGoogle Scholar
• MasumotoAMohriMShimokawaHUrakamiLUsuiMTakeshitaASuppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic anginaCirculation2002105131545154711927519
   PubMed Web of Science ®Google Scholar
• BussemakerEHerbrigKPistroschFPalmCPassauerJRole of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipientsAtherosclerosis2009207256757219717154
   PubMed Web of Science ®Google Scholar
• ChanCKMakJCManRYVanhouttePMRho kinase inhibitors prevent endothelium-dependent contractions in the rat aortaJ Pharmacol Exp Ther2009329282082619193928
   PubMedGoogle Scholar
• Abou-RayaAAbou-RayaSHelmiiMStatins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcersJ Rheumatol20083591801180818709692
   PubMed Web of Science ®Google Scholar
• ColeiroBMarshallSEDentonCPTreatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetineRheumatology (Oxford)20014091038104311561116
   PubMed Web of Science ®Google Scholar
• PopeJFenlonDThompsonAKetanserin for Raynaud’s phenomenon in progressive systemic sclerosisCochrane Database Syst Rev20002CD00095410796396
   PubMedGoogle Scholar
• HerrickALPathogenesis of Raynaud’s phenomenonRheumatology (Oxford)200544558759615741200
   PubMed Web of Science ®Google Scholar